Comments to USP: <476> and <1086> Impurities in Drug Substances and Drug Products

Share page:
Docket Number:
C133393 and C13392

CHPA strongly supports USP's efforts to address impurity control in drug substances and products. Overall the newly revised chapters provide reasonable guidance and direction for controlling organic impurities.

Related Posts

Plastic and Product Packaging

Consumer Medical Devices